NCT00539669已完成2 期
TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 47
- 试验地点
- 2
- 主要终点
- The response rate will be determined by the number of patients with complete and partial responses according to the Modified SWOG Response Criteria. The progression free survival, duration of response and survival are evaluated.
研究概览
简要总结
Evaluate response rate of Docetaxel in combination with Carboplatin or Cisplatin as first line chemotherapy in epithelial ovarian cancer. Assess the progression free survival, tolerance, duration of response and survival in the same patient population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed epithelial ovarian carcinoma. Patients with peritoneal carcinomatosis are also eligible, without necessarily having histological proof of a primary source in the ovary, provided that the tumour is not mucin-secreting, and that there is no evidence of a primary fallopian tube cancer (see
排除标准
- •Female, aged 18 or over- FIGO stages Ic-IV with or without successful cytoreductive surgery at staging laparotomy. Stage Ic patients will be limited to those with malignant cells in ascitic fluid, peritoneal washings or with tumour on the surface of the ovary
- •Patients with ruptured capsule as the only evidence of stage Ic will not be eligible for entry into the study.
- •Exclusion Criteria:
- •ECOG performance status > 2
- •Prior treatment with chemotherapy or radiotherapy.
- •Patients with, pre-existing fluid retention such as pleural effusion, pericardial effusion and ascites are not excluded from the study, but should be monitored closely for any deterioration. Efforts should be made to determine by cytological analysis whether any significant pre-existing fluid collections are due to ovarian cancer, and subsequent drainage is recommended before initiating chemotherapy.
- •Inadequate bone marrow function defined as neutrophils < 1.5 x 109/l or platelets < 100 x 109/l.
- •Inadequate renal function as defined by serum creatinine > 1.25 x upper limit of normal.
- •Inadequate liver function as defined by bilirubin > upper limit of normal or AST/ALT > 1.5 x upper limit of normal or ALP > 3 x upper limit of normal.
- •Concurrent severe and/or uncontrolled co-morbid medical condition (i.e. uncontrolled infection, hypertension, ischaemic heart disease, myocardial infarction within previous 6 months, congestive heart failure)
- •Patients with mixed mesodermal tumours.
- •Patients with borderline ovarian tumours or tumours termed 'possibly malignant'.
- •Adenocarcinoma of unknown origin, if histologically shown to be mucin-secreting cancer or thought to be possible primary fallopian tube carcinoma.
- •History of previous malignancy within the previous 5 years (except curatively treated carcinoma in situ of the uterine cervix, or basal cell carcinoma of the skin), or concurrent malignancy (e.g. coexisting endometrial cancer) .
- •History of prior serious allergic reactions (e.g. anaphylactic shock).
- •History of other relative contraindications to corticosteroid administration
- •Pregnant or lactating women (or potentially fertile women not using adequate contraception).
- •Symptomatic peripheral neuropathy > NCIC-CTC grade II.
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
结局指标
主要结局
The response rate will be determined by the number of patients with complete and partial responses according to the Modified SWOG Response Criteria. The progression free survival, duration of response and survival are evaluated.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) PatientsHormone-Refractory Prostate CancerNCT00675545National University Hospital, Singapore2
已完成
2 期
A phase II study of docetaxel/carboplatin as secondline treatment in patients with refractory or relapsed SCLCrefractory small cell lungcancerSCLC-ED10006436NL-OMON33924Jeroen Bosch Ziekenhuis50
进行中（未招募）
不适用
A phase II study of docetaxel/carboplatin as secondline treatment in patients with refractory or relapsed SCLCpatients with refractory or relapsed small cell lung cancerMedDRA version: 8.1Level: LLTClassification code 10041067Term: Small cell lung cancerEUCTR2006-004847-47-NLJeroen Bosch - Groot Ziekengasthuis
已完成
3 期
TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHNCarcinoma, Squamous CellNCT00539630Sanofi86
已完成
2 期
A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate CancerProstate CancerNCT00134706Dana-Farber Cancer Institute30